Medifocus Inc. (TSXV-MFS)

Recent Achievements

On July 25, 2012 Medifocus announced that it had completed the purchase of all Prolieve (R) assests from Boston Scientific Corporation. Prolieve is FDA approved for the treatment of Benign Prostatic Hyperplasia (BPH).

On July 19, 2011 Medifocus announced that it had successfully initiated its first two clinical study sites to begin its Pivotal Phase III study for the treatment of large breast cancers.

On March 30, 2011, Medifocus announced the appointment of Ernie Eves, QC, to the Board of Directors of Medifocus, Inc.

On March 21, 2011, Medifocus announced that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight.

On March 9, 2010, Medifocus announced that it had received IDE approval from the FDA to initiate its pivotal phase III clinical trial for breast cancer treatment. The IDE clearance from the FDA to start the pivotal studies in the United States is a significant strategic milestone for Medifocus towards global commercialization of the Microfocus APA 1000 thermotherapy system for breast cancer treatment.

On January 12, 2010, Medifocus announced that positive results of its breast cancer treatment studies were published in a review article in the Annals of Surgical Oncology. The article reviewed four clinical studies of the Medifocus APA 1000 thermotherapy system for patients with early-stage breast cancer and for patients with large breast cancer tumors.

Medifocus, Inc. (TSXV-MFS, OTC-MDFZF.PK)
© 2007 - 2023 Medifocus. All Rights Reserved. Legal Disclaimers